Skip to main content
رجوع
TWAPF logo

Towa Pharmaceutical Co., Ltd.

جودة البيانات: 100%
ذروة شراء
TWAPF
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 16.83
KWD 0.00 (0.00%)
القيمة السوقية: 828.51M
نطاق اليوم
KWD 16.83 KWD 25.33
نطاق 52 أسبوعًا
KWD 16.83 KWD 25.33
حجم التداول
200
متوسط 50 يوم / 200 يوم
KWD 16.83 / KWD 16.83
الإغلاق السابق
KWD 16.83

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 0.0 0.3
P/B 0.0 2.9
ROE % 11.6 3.7
Net Margin % 7.3 3.8
Rev Growth 5Y % 13.8 10.0
D/E 1.4 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 505.866
KWD 493.336 – KWD 514.341
330 B 1
FY2029 KWD 476.251
KWD 464.455 – KWD 484.230
330 B 1
FY2028 KWD 440.929
KWD 430.008 – KWD 448.316
310 B 1

النقاط الرئيسية

Revenue grew 13.78% annually over 5 years — strong growth
Earnings grew 17.39% over the past year
ROE of 11.59% — decent returns on equity
Negative free cash flow of -7.82B
P/E of 0.04 — trading at a low valuation
PEG of 0.54 suggests growth is underpriced

النمو

Revenue Growth (5Y)
13.78%
Revenue (1Y)13.89%
Earnings (1Y)17.39%
FCF Growth (3Y)N/A

الجودة

Return on Equity
11.59%
ROIC4.33%
Net Margin7.31%
Op. Margin8.95%

الأمان

Debt / Equity
1.35
Current Ratio2.81
Interest Coverage14.29

التقييم

P/E Ratio
0.04
P/B Ratio0.00
EV/EBITDA8.02
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 13.89% Revenue Growth (3Y) 11.49%
Earnings Growth (1Y) 17.39% Earnings Growth (3Y) 193.70%
Revenue Growth (5Y) 13.78% Earnings Growth (5Y) 7.99%
Profitability
Revenue (TTM) 259.59B Net Income (TTM) 18.99B
ROE 11.59% ROA 4.03%
Gross Margin 36.49% Operating Margin 8.95%
Net Margin 7.31% Free Cash Flow (TTM) -7.82B
ROIC 4.33% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.35 Current Ratio 2.81
Interest Coverage 14.29 Dividend Yield 0.02%
Valuation
P/E Ratio 0.04 P/B Ratio 0.00
P/S Ratio 0.00 PEG Ratio 0.54
EV/EBITDA 8.02 Dividend Yield 0.02%
Market Cap 828.51M Enterprise Value 186.34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 259.59B 227.93B 208.86B 165.62B 154.90B
Net Income 18.99B 16.17B 2.20B 15.91B 13.96B
EPS (Diluted) 385.71 328.59 44.72 316.19 271.93
Gross Profit 94.73B 81.38B 72.71B 70.19B 65.45B
Operating Income 23.24B 17.65B 5.51B 19.21B 19.92B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 470.82B 430.65B 371.35B 329.94B 245.67B
Total Liabilities 299.20B 274.76B 234.45B 197.77B 129.07B
Shareholders' Equity 171.62B 155.89B 136.89B 132.17B 116.60B
Total Debt 230.98B 202.36B 173.07B 144.13B 84.77B
Cash & Equivalents 45.47B 29.65B 24.26B 32.83B 22.92B
Current Assets 247.31B 217.72B 182.99B 166.86B 137.29B
Current Liabilities 87.94B 80.12B 78.53B 115.07B 51.52B

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#542 of 618
12

النشاط الأخير

دخل Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026